Markers for Diagnosing Pancreatic Cancer
Author Information
Author(s): Zapata Mauricio, Cohen Cynthia, Siddiqui Momin T
Primary Institution: Emory University Hospital
Hypothesis
The study aims to assess the diagnostic utility of SMAD4, CK19, and CA19-9 in confirming the pancreatic origin of tumors.
Conclusion
The study found that SMAD4, CK19, and CA19-9 are useful markers for confirming the diagnosis of pancreatic adenocarcinoma.
Supporting Evidence
- 80% of pancreatic adenocarcinoma cases were positive for SMAD4.
- 100% of cases were positive for CK19 and CA19-9.
- SMAD4 was negative in all cases of colonic and pulmonary adenocarcinoma.
Takeaway
Doctors can use special tests to check for certain markers in pancreatic cancer, which helps them know if the cancer started in the pancreas or came from somewhere else.
Methodology
A retrospective review of clinical data was conducted to identify patients with proven primary pancreatic adenocarcinoma, using fine needle aspiration samples and immunohistochemical staining.
Limitations
The study primarily focused on a small sample size and may not represent all cases of pancreatic adenocarcinoma.
Participant Demographics
The study included 25 patients with primary pancreatic adenocarcinoma, primarily affecting individuals aged 60-80, with a higher incidence in males and certain ethnic groups.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website